This statistic displays the average time between a combination therapy gaining marketing authorization and patient access in European countries as of January 1, 2024. According to the data, Switzerland had an average time of 201 days between authorization and patient access for combination therapies (for therapies launched from 2018 to 2021), compared to around 760 days in Poland.
Average time between marketing authorization and patient access for combination therapies in Europe as of 2024, by country
(in days)
Data collected is for drugs launched from 2019 to 2022. In most countries, availability equates to granting of access to the reimbursement list, except in DK, FI, NO, SE some hospital products are not covered by the general reimbursement scheme. The time to availability (formerly known as length of delay) is the days between EMA marketing authorization and the date of availability to patients.Â
* These countries did not complete a full dataset and therefore availability may be unrepresentative. ** The source mentions that it does not consider France's system of temporary authorization for some products, which means this time will be higher than in reality. *** MHRA’s Early Access to Medicines Scheme provides access before marketing authorization but is not included within this analysis, and would reduce the overall days for a small subset of medicines.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
IQVIA, & EFPIA. (June 25, 2024). Average time between marketing authorization and patient access for combination therapies in Europe as of 2024, by country (in days) [Graph]. In Statista. Retrieved July 17, 2024, from https://www.statista.com/statistics/1248725/europe-time-between-combination-therapies-authorization-and-access/
IQVIA, und EFPIA. "Average time between marketing authorization and patient access for combination therapies in Europe as of 2024, by country (in days)." Chart. June 25, 2024. Statista. Accessed July 17, 2024. https://www.statista.com/statistics/1248725/europe-time-between-combination-therapies-authorization-and-access/
IQVIA, EFPIA. (2024). Average time between marketing authorization and patient access for combination therapies in Europe as of 2024, by country (in days). Statista. Statista Inc.. Accessed: July 17, 2024. https://www.statista.com/statistics/1248725/europe-time-between-combination-therapies-authorization-and-access/
IQVIA, and EFPIA. "Average Time between Marketing Authorization and Patient Access for Combination Therapies in Europe as of 2024, by Country (in Days)." Statista, Statista Inc., 25 Jun 2024, https://www.statista.com/statistics/1248725/europe-time-between-combination-therapies-authorization-and-access/
IQVIA & EFPIA, Average time between marketing authorization and patient access for combination therapies in Europe as of 2024, by country (in days) Statista, https://www.statista.com/statistics/1248725/europe-time-between-combination-therapies-authorization-and-access/ (last visited July 17, 2024)
Average time between marketing authorization and patient access for combination therapies in Europe as of 2024, by country (in days) [Graph], IQVIA, & EFPIA, June 25, 2024. [Online]. Available: https://www.statista.com/statistics/1248725/europe-time-between-combination-therapies-authorization-and-access/
